Trillium Therapeutics Inc.
TRIL
TRIL was delisted on the 16th of November, 2021.
22 hedge funds and large institutions have $14.4M invested in Trillium Therapeutics Inc. in 2017 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 11 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
4% less capital invested
Capital invested by funds: $14.9M → $14.4M (-$526K)
24% less funds holding
Funds holding: 29 → 22 (-7)
64% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$166K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
+$136K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$130K |
| 4 |
NLVP
New Leaf Venture Partners
New York
|
+$43.4K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$26.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$622K |
| 2 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$470K |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$160K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$143K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$139K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OAM
26
Oxford Asset Management
Oxford,
United Kingdom
| – | -$139K | -24,660 | Closed |
|
|
VKH
27
Virtu KCG Holdings
New York
| – | -$127K | -22,470 | Closed |
|
|
SSA
28
Schonfeld Strategic Advisors
New York
| – | -$125K | -22,047 | Closed |
|
29
Jane Street
New York
| – | -$109K | -19,230 | Closed |
|
|
KPF
30
K2 Principal Fund
Toronto,
Ontario, Canada
| – | -$92K | -16,239 | Closed |
|
|
TI
31
Trexquant Investment
Stamford,
Connecticut
| – | -$84K | -14,902 | Closed |
|
|
TC
32
TFS Capital
West Chester,
Pennsylvania
| – | -$58K | -10,247 | Closed |
|
33
JP Morgan Chase
New York
| – | -$27K | -4,800 | Closed |
|
TRIL Hedge Fund Activity: Q1 2017 in Review
22 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q1 2017, worth a combined $14.4M — down 3.5% from $14.9M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of TRIL and 4 opened new positions — a net loss of 7 holders — while 4 trimmed existing stakes and 7 added.
The largest buyer was Sectoral Asset Management, adding an estimated $166K. The largest seller was Opaleye Management, exiting entirely with an estimated $622K sold.
- 22 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q1 2017, down from 29 in Q4 2016.
- Funds reported $14.4M of Trillium Therapeutics Inc. stock for Q1 2017, down 3.5% quarter-over-quarter.
- 4 funds opened new Trillium Therapeutics Inc. positions in Q1 2017 and 11 closed out, a net change of -7 holders.
- The largest Trillium Therapeutics Inc. buyer in Q1 2017 was Sectoral Asset Management, an estimated $166K added.
- The largest Trillium Therapeutics Inc. seller in Q1 2017 was Opaleye Management, an estimated $622K sold.
Based on aggregated 13F filings for Q1 2017.